Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure
Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure
复制标题
DOI：
10.1002/pds.2112
复制
发表时间：
2011-04-01
影响因子：
2.6
通讯作者：
Park, Byung-Joo
中科院分区：
文献类型：
--
作者：
Seong, Jong-Mi;Choi, Nam-Kyong;Park, Byung-Joo
目的比较噻唑烷二酮类药物（TZDs）在老年2型糖尿病伴和不伴心力衰竭（HF）患者中的处方模式。方法使用韩国健康保险审查与评估服务（HIRA）的国家健康保险索赔数据库。研究对象为2005年7月1日至2006年6月30日期间至少服用一种降糖药的2型糖尿病老年患者。根据HF的存在对患者进行分组。比较两组接受TZD的患者比例，并按糖尿病药物治疗方案（单药治疗和联合治疗）分层。TZD处方模式的差异进行了研究，在所有的医疗保健水平，包括：初级，二级和三级医疗facility.Results 357 855老年2型糖尿病患者，24 746例患者有HF。10.4%的HF患者和8.8%的非HF患者使用TZD（p < 0.01）。在联合治疗组中，合并和不合并HF的患者中接受TZD的患者比例分别为17.9%和14.4%（p < 0.01）。在基层医疗机构中，TZD类药物在HF患者中的使用比例为5.6%，在非HF患者中的使用比例为4.6%（p < 0.01）。2型糖尿病患者的饮食习惯有哪些？此外，他们应仔细监测TZD对HF患者的影响。版权所有（C）2011约翰威利父子有限公司
Purpose To compare the prescribing patterns of thiazolidinediones (TZDs) in elderly patients with type 2 diabetes with and without heart failure (HF).Methods The national health insurance claims database from the Health Insurance Review & Assessment Service (HIRA), Korea was used. Elderly patients with type 2 diabetes taking at least one hypoglycemic agent were studied between July 1, 2005 and June 30, 2006. Patients were grouped according to the presence of HF. The proportion of patients receiving TZDs were compared between the two groups, and stratified by their diabetes medication regimen (monotherapy and combination therapy). The difference in the patterns of TZD prescribed was studied across all health care levels including: primary, secondary, and tertiary care facilities.Results Among 357 855 elderly patients with type 2 diabetes, 24 746 patients had HF. TZDs were prescribed to 10.4% of the patients with HF and 8.8% of the patients without HF (p < 0.01). In the combination therapy group, the proportion of patients receiving TZDs was 17.9% and 14.4% in patients with and without HF, respectively (p < 0.01). In the primary care setting, the proportion of TZD prescriptions in patients with HF was 5.6% and it was 4.6% in patients without HF (p < 0.01).Conclusions TZDs were frequently prescribed to patients with HF, even though the TZDs were contraindicated in patients with HF. Health care professionals should consider alternative therapies for patients with type 2 diabetes mellitus. In addition, they should carefully monitor the impact of TZD use in patients with HF. Copyright (C) 2011 John Wiley & Sons, Ltd.